包皮切除武清区龙济医院(天津武清区龙济医院泌尿专科医院介绍) (今日更新中)

SAN DIEGO (KGTV) -- In three weeks San Diego County will elect its next district attorney,  and in a recent poll a large number of voters indicated that they're still undecided. The results of our scientific 10News Union-Tribune poll shows the battle between Summer Stephan and challenger Genevieve Jones-Wright is wide open. If the election were held today, Summer Stephan would get 35 percent of the vote. Genevieve Jones-Wright would get 22 percent and 43 percent of those polled said they are undecided. "Those polls are consistent with what our campaign research shows," Jones-Wright told 10News. "We knew we were up against a political machine and it really is no surprise to me that she's up on the polls."Progressive candidate Jones-Wright says Stephan got a head start, by being appointed to the district attorney job when Bonnie Dumanis left. Jones-Wright said she thinks the poll shows her campaign is gaining steam.Stephan was encouraged by the poll numbers. "This is very encouraging, what you're telling me, because it shows that what we're doing is working," she told 10News. "That San Diegans are enjoying that we're one of the safest urban regions in the country and that they really prefer experience over an experiment."The poll shows that Stephan's voter base is republican, white and over the age of 35. It shows that Wright's voter base is younger, more racially mixed and primarily democratic. On Monday, Summer Stephan pulled out of a community forum, one which both she and Genevieve Jones-Wright accepted to face off. 1581

SAN DIEGO (KGTV) — It’s one of the few drugs shown to help fight the novel coronavirus, and a large federal study on remdesivir just entered a new phase.Previous research sponsored by the National Institute for Allergy and Infectious Disease showed remdesivir shortened recovery time in hospitalized COVID-19 patients on average from 15 days to 11 days.Now scientists and doctors are racing to find the perfect cocktail against COVD-19 by blending remdesivir with other drugs.California-based Gilead Sciences originally developed the drug to fight Ebola, but remdesivir was never approved. Gilead Sciences has offices in Oceanside.The drug works by interrupting the virus’ ability to replicate.“Remdesivir acts by shutting down virus production,” said Dr. Peter Chin-Hong, an infectious disease expert at University of California San Francisco. “It just forces the virus to stop making virus children.”Dr. Chin-Hong is studying remdesivir as part of the NIAID research.The problem is that stopping the virus from replicating isn’t enough for some severely ill patients. They suffer from a second problem: massive inflammation from the immune system’s war with the virus.That’s why scientists are trying a cocktail approach.“You have the virus to take care of, but you also have the body's response to the virus, which is inflammation, that you also have to take care of,” said Dr. Chin-Hong.Researchers started testing the first drug cocktail in May, using an arthritis drug called baricitinib that tames inflammation.But as the data on that part of the study gets crunched, researchers began testing the second cocktail this month, a combination of remdesivir and interferon beta.“Interferon beta is something we produce naturally to fight viruses,” said Dr. Chin-Hong. He said studies have shown people who don’t produce enough interferon beta struggle to fight off the virus.Researchers selected interferon beta after two small studies showed promising results against the coronavirus.Interferon beta can both reduce inflammation and kill viruses, so doctors are hoping it will be a potent one-two punch with remdesivir.Dr. Chin-Hong said he and other researchers started administering the new cocktail this month.Some patients will receive the cocktail, some will receive a placebo, and some will get remdesivir only. This kind of clinical trial is called an adaptive trial, which the FDA started encouraging in 2004. After each phase, the winning drug or cocktail will be tested against a new challenger.Dr. Chin-Hong said the eventual cocktail may include three or more drugs, similar to HIV medication. 2617

SAN DIEGO (KGTV) — It's become the first question when considering a cell phone plan: How's the coverage?In San Diego, AT&T customers may find they have better luck than other carriers, according to a study by PC Mag.Locally, 19 locations were tested around the county — from Chula Vista to La Jolla and out to the College East area — between May 7 and June 1, 2019. Testers ran speed software every two minutes on sets of Samsung Galaxy S10 series phones for about 15 minutes in each location.For San Diego County, AT&T scored the "fastest" title ahead of T-Mobile, Verizon, and Sprint."In San Diego, AT&T had nearly double the average download speed of the next-fastest network, with excellent reliability," PC Mag writes. "The carrier has been spreading its 5G Evolution LTE improvements up and down the California coastline, and we really saw the positive benefits this year."AT&T's average download speed was recorded at 90.7 Mbps, compared to Sprint's 51.5 Mbps, T-Mobile's 44.2 Mbps, and Verizon's 36.4 Mbps averages. Uploads over 2 Mbps were successful 97% of the time on AT&T's network, 96% on Verizon, 94% on T-Mobile, and 74% on Sprint.Overall, AT&T, T-Mobile, and Verizon were all given a 100% reliability score. But when it came to speed of network, AT&T grabbed a perfect score, followed by T-Mobile, Verizon, and Sprint."AT&T and Verizon both plan to bring 5G to San Diego this year. As they're millimeter wave networks, you should expect to see them in dense parts of downtown and the Gaslamp District; you'll be relying on 4G in most of the sprawling San Diego metro area for years to come," PC Mag writes.PC Mag's full study and methodology can be found here. 1717

SAN DIEGO (KGTV) – Major developments came late Tuesday to create countywide policy changes related to policing reforms. After several hours of testimony and public comments, all three parts of a policy package were voted on and passed by the San Diego County Board of Supervisors during a special meeting.It was introduced by Supervisor Nathan Fletcher who said it was designed to create more transparency and to start to change systemic and structural racism that has caused pain and harm to generations of African American people.The three proposals that passed include launching mobile crisis response teams made of social workers and clinicians instead of law enforcement for some mental health and homeless services and emergency calls, increasing independence and strengthening oversight of the Citizen’s Law Enforcement Review Board and establishing an Office of Equity and Racial Justice.ABC10 News listened in as callers weighed in on both sides of the debate over the creation of an Office of Equity and Racial Justice. Many callers were in favor of its creation. Others argued that the County should consider a bolstered version brought forth by civil rights activist Rev. Shane Harris who recommended that the County increase the number of staffers assigned to the Office and increase its budget to million.The Board of Supervisors decided that the passed proposal for the Office of Equity and Racial Justice will need to be reviewed by an independent consultant and the Human Relations Commission will need to provide guidance on the Office’s mission.Late Tuesday, the Office of Supervisor Nathan Fletcher sent ABC10 News the following statement:“The Board of Supervisors today voted to support the entire Racial Justice and Law Enforcement Realignment Policy Package authored by Supervisor Nathan Fletcher and crafted in partnership with respected leaders from the Black community. The three policies will strengthen the Citizen’s Law Enforcement Review Board Authority and Independence, create an Office of Equity and Racial Justice for the County of San Diego and launch countywide Mobile Crisis Response Teams (MCRT) to allow trained mental health clinicians, not law enforcement, to respond to non-violent service needs. The group released the following statement after the vote:‘The community called for change, and today’s action is a step forward. Tackling deep seeded issues of systemic and structural racism is not going to be easy and at times it will be uncomfortable, but, we will be a better organization and a better people because of the actions we take to support racial justice and realigning law enforcement. We are thankful for the considerable community input we received to shape these policies and tremendous support that helped ensure their passage. The most important days of this work are in front of us and we look forward to a continued partnership with Black community leaders as we put these policies into practice.’” 2972

SAN DIEGO (KGTV) — In some of the most severe cases of COVID-19, doctors are finding it’s not the coronavirus making people critically ill.It’s their own immune system, and a San Diego-based biotech company thinks it has an answer.La Jolla-based INmune Bio announced Tuesday it has FDA approval to begin a Phase 2 clinical trial on its inflammation fighting drug, Quellor.In many of the sickest COVID patients, doctors have noticed their blood is filled with high levels of immune proteins called cytokines. Cytokines act as messengers between cells and the virus can cause them to go haywire, setting off what’s known as a cytokine storm.In a cytokine storm, the body’s immune system starts to attack its own cells and tissues rather than the virus. During the Spanish Flu of 1918, many of the deaths were caused by cytokine storms.“You need to control the cytokine storm to keep patients from getting sick,” said INmune Bio’s CEO Dr. R.J. Tesi.There are several different types of cytokines. A drug undergoing testing in a federal trial with remdesivir targets a cytokine called beta interferon.The San Diego biotech’s drug Quellor suppresses a very specific cytokine called soluble tumor necrosis factor, which Dr. Tesi calls “the master cytokine” because of its role in triggering other immune proteins.Dr. Tesi said this particular cytokine may contribute to another troubling issue with COVID-19: blood clotting.“When they write the history of COVID-19, the clots are going to be the bad guy,” Dr. Tesi said. “These blood clots go off everywhere and they gum up the works. They make it so the lungs can't work. They make it so the kidneys can't work. They make it so the heart is screwed up. Make it so you have strokes.”INmune Bio, which is publicly traded but has just six full-time employees, is hoping its drug can address both the blood clots and the inflammation.The company plans to enroll 366 hospitalized COVID-19 patients for a Phase 2 trial to see if intervention with Quellor can keep people off ventilators and out of the ICU. 2053

来源：资阳报